Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism

Epidemiological studies have demonstrated that the Mediterranean diet, which is rich in resveratrol, is associated with a significantly reduced risk of cardiovascular disease. However, the molecular mechanisms that underlie the beneficial effects of resveratrol on cardiovascular function remain inco...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2013-08, Vol.62 (2), p.359-366
Hauptverfasser: Carrizzo, Albino, Puca, Annibale, Damato, Antonio, Marino, Marina, Franco, Elio, Pompeo, Franco, Traficante, Anna, Civitillo, Fabio, Santini, Luigi, Trimarco, Valentina, Vecchione, Carmine
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 366
container_issue 2
container_start_page 359
container_title Hypertension (Dallas, Tex. 1979)
container_volume 62
creator Carrizzo, Albino
Puca, Annibale
Damato, Antonio
Marino, Marina
Franco, Elio
Pompeo, Franco
Traficante, Anna
Civitillo, Fabio
Santini, Luigi
Trimarco, Valentina
Vecchione, Carmine
description Epidemiological studies have demonstrated that the Mediterranean diet, which is rich in resveratrol, is associated with a significantly reduced risk of cardiovascular disease. However, the molecular mechanisms that underlie the beneficial effects of resveratrol on cardiovascular function remain incompletely understood. Therefore, we set out to identify the molecular target(s) mediating the protective action of resveratrol on vascular function. To this end, we performed vascular reactivity studies to evaluate the effects of resveratrol on superior thyroid artery obtained from 59 patients with hypertension and dyslipidemia. We found that resveratrol evoked vasorelaxation and reduced endothelial dysfunction through the modulation of NO metabolism via (1) an 5′ adenosine monophosphate–activated protein kinase–mediated increase in endothelial NO synthase activity; (2) a rise in tetrahydrobiopterin levels, which also increases endothelial NO synthase activity; and (3) attenuation of vascular oxidative stress, brought about by overexpression of manganese superoxide dismutase via an nuclear factor erythroid–derived 2-like 2–dependent mechanism. The effects of resveratrol on acetylcholine vasorelaxation were also tested in vessels from patients with nonhypertensive nondyslipidemia undergoing thyroid surgery. In this setting, resveratrol failed to exert any effect. Thus, our finding that resveratrol reduces endothelial dysfunction, an early pathophysiological feature and independent predictor of poor prognosis in most forms of cardiovascular disease, supports the concept that the risk of vascular events could be further reduced by adherence to a set of dietary and behavioral guidelines.
doi_str_mv 10.1161/HYPERTENSIONAHA.111.01009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1406176895</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1406176895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4434-9acdec70b6f68d2addc56b8afca6f2894739d9d46ca7396b8e41af5f2b71a4da3</originalsourceid><addsrcrecordid>eNpdkF1v0zAUhi0EYmXsLyBzgcRNhh07TnJZbR2ttLXTvoCr6MR2qMFxOtvZ1H-PSwtIWDqyzznPeW2_CL2n5JRSQT_Nv13Pbu5my9vFajmdT1ORnhJKSP0CTWiR84wXgr1EE0JrntWUfj1Cb0L4QQjlnJev0VHOyoJxUk7Q440OT9pD9IPFi37jhycd8AMEOVrw-GJ0MprBYePwNUSjXQz4i4lrPN9utI_ahV0XnMLn22DNxijdG8DtFl8NKklE477j5Qpf6QjtYE3o36JXHdigTw77Mbq_mN2dzbPL1efF2fQyk5yz9GyQSsuStKITlcpBKVmItoJOgujyquYlq1WtuJCQTqmjOYWu6PK2pMAVsGP0ca-b_vQ46hCb3gSprQWnhzE0lBNBS1HVRULrPSr9EILXXbPxpge_bShpdo43_zmeirT57XiafXe4Zmx7rf5O_rE4AR8OQDIVbOfBSRP-cWVR1ozthPieex5s1D78tOOz9s1ag43rhqTFc1FlOaGMVCnLUuSc_QKeSZ3R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1406176895</pqid></control><display><type>article</type><title>Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Carrizzo, Albino ; Puca, Annibale ; Damato, Antonio ; Marino, Marina ; Franco, Elio ; Pompeo, Franco ; Traficante, Anna ; Civitillo, Fabio ; Santini, Luigi ; Trimarco, Valentina ; Vecchione, Carmine</creator><creatorcontrib>Carrizzo, Albino ; Puca, Annibale ; Damato, Antonio ; Marino, Marina ; Franco, Elio ; Pompeo, Franco ; Traficante, Anna ; Civitillo, Fabio ; Santini, Luigi ; Trimarco, Valentina ; Vecchione, Carmine</creatorcontrib><description>Epidemiological studies have demonstrated that the Mediterranean diet, which is rich in resveratrol, is associated with a significantly reduced risk of cardiovascular disease. However, the molecular mechanisms that underlie the beneficial effects of resveratrol on cardiovascular function remain incompletely understood. Therefore, we set out to identify the molecular target(s) mediating the protective action of resveratrol on vascular function. To this end, we performed vascular reactivity studies to evaluate the effects of resveratrol on superior thyroid artery obtained from 59 patients with hypertension and dyslipidemia. We found that resveratrol evoked vasorelaxation and reduced endothelial dysfunction through the modulation of NO metabolism via (1) an 5′ adenosine monophosphate–activated protein kinase–mediated increase in endothelial NO synthase activity; (2) a rise in tetrahydrobiopterin levels, which also increases endothelial NO synthase activity; and (3) attenuation of vascular oxidative stress, brought about by overexpression of manganese superoxide dismutase via an nuclear factor erythroid–derived 2-like 2–dependent mechanism. The effects of resveratrol on acetylcholine vasorelaxation were also tested in vessels from patients with nonhypertensive nondyslipidemia undergoing thyroid surgery. In this setting, resveratrol failed to exert any effect. Thus, our finding that resveratrol reduces endothelial dysfunction, an early pathophysiological feature and independent predictor of poor prognosis in most forms of cardiovascular disease, supports the concept that the risk of vascular events could be further reduced by adherence to a set of dietary and behavioral guidelines.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/HYPERTENSIONAHA.111.01009</identifier><identifier>PMID: 23753407</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Hagerstown, MD: American Heart Association, Inc</publisher><subject>Acetylcholine - pharmacology ; Arterial hypertension. Arterial hypotension ; Biological and medical sciences ; Biopterins - analogs &amp; derivatives ; Biopterins - blood ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Dyslipidemias - physiopathology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology ; Hypertension - physiopathology ; Medical sciences ; NF-E2-Related Factor 2 - physiology ; Nitric Oxide - metabolism ; Nitric Oxide Synthase Type III - metabolism ; Phosphorylation ; Resveratrol ; Stilbenes - pharmacology ; Superoxide Dismutase - metabolism ; Vasodilation - drug effects</subject><ispartof>Hypertension (Dallas, Tex. 1979), 2013-08, Vol.62 (2), p.359-366</ispartof><rights>2013 American Heart Association, Inc</rights><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4434-9acdec70b6f68d2addc56b8afca6f2894739d9d46ca7396b8e41af5f2b71a4da3</citedby><cites>FETCH-LOGICAL-c4434-9acdec70b6f68d2addc56b8afca6f2894739d9d46ca7396b8e41af5f2b71a4da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3674,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27579339$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23753407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carrizzo, Albino</creatorcontrib><creatorcontrib>Puca, Annibale</creatorcontrib><creatorcontrib>Damato, Antonio</creatorcontrib><creatorcontrib>Marino, Marina</creatorcontrib><creatorcontrib>Franco, Elio</creatorcontrib><creatorcontrib>Pompeo, Franco</creatorcontrib><creatorcontrib>Traficante, Anna</creatorcontrib><creatorcontrib>Civitillo, Fabio</creatorcontrib><creatorcontrib>Santini, Luigi</creatorcontrib><creatorcontrib>Trimarco, Valentina</creatorcontrib><creatorcontrib>Vecchione, Carmine</creatorcontrib><title>Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Epidemiological studies have demonstrated that the Mediterranean diet, which is rich in resveratrol, is associated with a significantly reduced risk of cardiovascular disease. However, the molecular mechanisms that underlie the beneficial effects of resveratrol on cardiovascular function remain incompletely understood. Therefore, we set out to identify the molecular target(s) mediating the protective action of resveratrol on vascular function. To this end, we performed vascular reactivity studies to evaluate the effects of resveratrol on superior thyroid artery obtained from 59 patients with hypertension and dyslipidemia. We found that resveratrol evoked vasorelaxation and reduced endothelial dysfunction through the modulation of NO metabolism via (1) an 5′ adenosine monophosphate–activated protein kinase–mediated increase in endothelial NO synthase activity; (2) a rise in tetrahydrobiopterin levels, which also increases endothelial NO synthase activity; and (3) attenuation of vascular oxidative stress, brought about by overexpression of manganese superoxide dismutase via an nuclear factor erythroid–derived 2-like 2–dependent mechanism. The effects of resveratrol on acetylcholine vasorelaxation were also tested in vessels from patients with nonhypertensive nondyslipidemia undergoing thyroid surgery. In this setting, resveratrol failed to exert any effect. Thus, our finding that resveratrol reduces endothelial dysfunction, an early pathophysiological feature and independent predictor of poor prognosis in most forms of cardiovascular disease, supports the concept that the risk of vascular events could be further reduced by adherence to a set of dietary and behavioral guidelines.</description><subject>Acetylcholine - pharmacology</subject><subject>Arterial hypertension. Arterial hypotension</subject><subject>Biological and medical sciences</subject><subject>Biopterins - analogs &amp; derivatives</subject><subject>Biopterins - blood</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Dyslipidemias - physiopathology</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</subject><subject>Hypertension - physiopathology</subject><subject>Medical sciences</subject><subject>NF-E2-Related Factor 2 - physiology</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase Type III - metabolism</subject><subject>Phosphorylation</subject><subject>Resveratrol</subject><subject>Stilbenes - pharmacology</subject><subject>Superoxide Dismutase - metabolism</subject><subject>Vasodilation - drug effects</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF1v0zAUhi0EYmXsLyBzgcRNhh07TnJZbR2ttLXTvoCr6MR2qMFxOtvZ1H-PSwtIWDqyzznPeW2_CL2n5JRSQT_Nv13Pbu5my9vFajmdT1ORnhJKSP0CTWiR84wXgr1EE0JrntWUfj1Cb0L4QQjlnJev0VHOyoJxUk7Q440OT9pD9IPFi37jhycd8AMEOVrw-GJ0MprBYePwNUSjXQz4i4lrPN9utI_ahV0XnMLn22DNxijdG8DtFl8NKklE477j5Qpf6QjtYE3o36JXHdigTw77Mbq_mN2dzbPL1efF2fQyk5yz9GyQSsuStKITlcpBKVmItoJOgujyquYlq1WtuJCQTqmjOYWu6PK2pMAVsGP0ca-b_vQ46hCb3gSprQWnhzE0lBNBS1HVRULrPSr9EILXXbPxpge_bShpdo43_zmeirT57XiafXe4Zmx7rf5O_rE4AR8OQDIVbOfBSRP-cWVR1ozthPieex5s1D78tOOz9s1ag43rhqTFc1FlOaGMVCnLUuSc_QKeSZ3R</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Carrizzo, Albino</creator><creator>Puca, Annibale</creator><creator>Damato, Antonio</creator><creator>Marino, Marina</creator><creator>Franco, Elio</creator><creator>Pompeo, Franco</creator><creator>Traficante, Anna</creator><creator>Civitillo, Fabio</creator><creator>Santini, Luigi</creator><creator>Trimarco, Valentina</creator><creator>Vecchione, Carmine</creator><general>American Heart Association, Inc</general><general>Lippincott Williams &amp; Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201308</creationdate><title>Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism</title><author>Carrizzo, Albino ; Puca, Annibale ; Damato, Antonio ; Marino, Marina ; Franco, Elio ; Pompeo, Franco ; Traficante, Anna ; Civitillo, Fabio ; Santini, Luigi ; Trimarco, Valentina ; Vecchione, Carmine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4434-9acdec70b6f68d2addc56b8afca6f2894739d9d46ca7396b8e41af5f2b71a4da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetylcholine - pharmacology</topic><topic>Arterial hypertension. Arterial hypotension</topic><topic>Biological and medical sciences</topic><topic>Biopterins - analogs &amp; derivatives</topic><topic>Biopterins - blood</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Dyslipidemias - physiopathology</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology</topic><topic>Hypertension - physiopathology</topic><topic>Medical sciences</topic><topic>NF-E2-Related Factor 2 - physiology</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase Type III - metabolism</topic><topic>Phosphorylation</topic><topic>Resveratrol</topic><topic>Stilbenes - pharmacology</topic><topic>Superoxide Dismutase - metabolism</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carrizzo, Albino</creatorcontrib><creatorcontrib>Puca, Annibale</creatorcontrib><creatorcontrib>Damato, Antonio</creatorcontrib><creatorcontrib>Marino, Marina</creatorcontrib><creatorcontrib>Franco, Elio</creatorcontrib><creatorcontrib>Pompeo, Franco</creatorcontrib><creatorcontrib>Traficante, Anna</creatorcontrib><creatorcontrib>Civitillo, Fabio</creatorcontrib><creatorcontrib>Santini, Luigi</creatorcontrib><creatorcontrib>Trimarco, Valentina</creatorcontrib><creatorcontrib>Vecchione, Carmine</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carrizzo, Albino</au><au>Puca, Annibale</au><au>Damato, Antonio</au><au>Marino, Marina</au><au>Franco, Elio</au><au>Pompeo, Franco</au><au>Traficante, Anna</au><au>Civitillo, Fabio</au><au>Santini, Luigi</au><au>Trimarco, Valentina</au><au>Vecchione, Carmine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>2013-08</date><risdate>2013</risdate><volume>62</volume><issue>2</issue><spage>359</spage><epage>366</epage><pages>359-366</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>Epidemiological studies have demonstrated that the Mediterranean diet, which is rich in resveratrol, is associated with a significantly reduced risk of cardiovascular disease. However, the molecular mechanisms that underlie the beneficial effects of resveratrol on cardiovascular function remain incompletely understood. Therefore, we set out to identify the molecular target(s) mediating the protective action of resveratrol on vascular function. To this end, we performed vascular reactivity studies to evaluate the effects of resveratrol on superior thyroid artery obtained from 59 patients with hypertension and dyslipidemia. We found that resveratrol evoked vasorelaxation and reduced endothelial dysfunction through the modulation of NO metabolism via (1) an 5′ adenosine monophosphate–activated protein kinase–mediated increase in endothelial NO synthase activity; (2) a rise in tetrahydrobiopterin levels, which also increases endothelial NO synthase activity; and (3) attenuation of vascular oxidative stress, brought about by overexpression of manganese superoxide dismutase via an nuclear factor erythroid–derived 2-like 2–dependent mechanism. The effects of resveratrol on acetylcholine vasorelaxation were also tested in vessels from patients with nonhypertensive nondyslipidemia undergoing thyroid surgery. In this setting, resveratrol failed to exert any effect. Thus, our finding that resveratrol reduces endothelial dysfunction, an early pathophysiological feature and independent predictor of poor prognosis in most forms of cardiovascular disease, supports the concept that the risk of vascular events could be further reduced by adherence to a set of dietary and behavioral guidelines.</abstract><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>23753407</pmid><doi>10.1161/HYPERTENSIONAHA.111.01009</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0194-911X
ispartof Hypertension (Dallas, Tex. 1979), 2013-08, Vol.62 (2), p.359-366
issn 0194-911X
1524-4563
language eng
recordid cdi_proquest_miscellaneous_1406176895
source MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
subjects Acetylcholine - pharmacology
Arterial hypertension. Arterial hypotension
Biological and medical sciences
Biopterins - analogs & derivatives
Biopterins - blood
Blood and lymphatic vessels
Cardiology. Vascular system
Dyslipidemias - physiopathology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hypertension - physiopathology
Medical sciences
NF-E2-Related Factor 2 - physiology
Nitric Oxide - metabolism
Nitric Oxide Synthase Type III - metabolism
Phosphorylation
Resveratrol
Stilbenes - pharmacology
Superoxide Dismutase - metabolism
Vasodilation - drug effects
title Resveratrol Improves Vascular Function in Patients With Hypertension and Dyslipidemia by Modulating NO Metabolism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A56%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resveratrol%20Improves%20Vascular%20Function%20in%20Patients%20With%20Hypertension%20and%20Dyslipidemia%20by%20Modulating%20NO%20Metabolism&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Carrizzo,%20Albino&rft.date=2013-08&rft.volume=62&rft.issue=2&rft.spage=359&rft.epage=366&rft.pages=359-366&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/HYPERTENSIONAHA.111.01009&rft_dat=%3Cproquest_cross%3E1406176895%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1406176895&rft_id=info:pmid/23753407&rfr_iscdi=true